2018 - RAS Dialogue Blog
-
Conversation with Dr. Shiva Malek and Dr. Christiaan KlijnSignaling downstream of RAS is subject to many levels of regulation. Inhibiting MEK seems to re-wire that regulation so that inhibitors of RAF kinases are more effective against cells driven by mutant KRAS.
-
Conversation with Scott Kopetz: RAS in Colorectal Cancer, Initiation and ResistanceMutated RAS genes are an important cause of colorectal cancers, and play a role in resistance to current drug therapies. Remarkably, patients whose cancer is progressing despite treatment often have multiple different RAS mutations in their tumors.
-
Combination Screens for Cancer Vulnerabilities: A Conversation with Kris WoodCancers driven by mutant KRAS are difficult to treat. Combining genetic screens with drugs that work downstream of mutant KRAS reveals cellular adaptations to uncontrolled growth that may be targeted.
-
Conversation with Elizabeth Jaffee: An Immuno-Oncology UpdateImmunotherapy is becoming part of the "standard of care" for many cancer patients. Elizabeth Jaffee describes how we got here and where we need to go in the future.
-
A Conversation About RAS DimersData are persuasive that RAS proteins are dimeric in living cells, but monomeric in vitro. Pasi Jänne, Chiara Ambrogio, and Frank McCormick discuss the significance of understanding RAS dimers for finding treatments for RAS cancers.